Actinium Pharmaceuticals (ATNM) Liabilities and Shareholders Equity (2010 - 2026)

Actinium Pharmaceuticals (ATNM) has reported Liabilities and Shareholders Equity for 17 consecutive years, with $45.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 33.81% year-over-year to $45.4 million; the TTM figure through Mar 2026 stood at $216.4 million (down 31.85% YoY), while the FY2025 annual figure was $51.8 million, down 32.67% from the prior year.
• Liabilities and Shareholders Equity slipped to $45.4 million in Q1 2026 per ATNM's latest filing, from $51.8 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $121.8 million in Q2 2022 and bottomed at $45.4 million in Q1 2026.
• Historically, Liabilities and Shareholders Equity has averaged $83.6 million across 5 years, with a median of $82.1 million in 2024.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity soared 44.22% — and 2026, when it slumped 33.81%.
• Actinium Pharmaceuticals' Liabilities and Shareholders Equity stood at $114.2 million in 2022, then dropped by 28.68% to $81.4 million in 2023, then declined by 5.58% to $76.9 million in 2024, then plunged by 32.67% to $51.8 million in 2025, then dropped by 12.24% to $45.4 million in 2026.
• Business Quant data shows ATNM's Liabilities and Shareholders Equity at $45.4 million in Q1 2026, $51.8 million in Q4 2025, and $56.2 million in Q3 2025.